Experienced investor, surgeon and biomedical engineer.
Founder & Managing Partner
Dr. Raymond Rackley is a renowned pelvic reconstructive surgeon who has also generated significant returns as a venture capitalist, while developing strong co-investing relationships with some of the region’s most active funders.
Currently, Dr. Rackley serves as a Professor of Surgery at the world’s premier Cleveland Clinic’s Glickman Urology Center for Pelvic Medicine and Reconstructive Surgery. Over 32 years, he has become a leading biomedical engineer, reconstructive surgeon and life-science industry consultant.
He has also been an active investor, making numerous venture health science and technology investments since 2002 while serving as a board advisor, investment committee member or limited partner in Serial Stage Venture Partners, an angel investor network, and several Midwest venture funds including Nirvana Healthcare Venture Fund, NDI Medical Fund, BioEnterprise’s Medical Growth Fund and NorthCoast Angels (NCA) Funds II & III.
As an active investor/advisor, Dr. Rackley has participated in multiple co-investing and venture partnering activities alongside regional venture funders such as First Analysis, Mutual Capital Partners, BlueTree Capital, JumpStart, BioEnterprise, NCA & Ventures and MI-12 managing partners while holding board and committee roles in several seed-series, early and late stage medical device and pharmaceutical companies.
Dr. Rackley earned his MD in Medicine from Case Western Reserve University Medical School and his BS in Biomedical Engineering from Duke Engineering.
Proven MedTech leader, investor and advisor.
Jonathan Lehmann is a MedTech leader, angel investor, and commercial consultant. He is a 20-year veteran of the space and is driven by the purpose of playing a role in the funding and commercializing of minimally-invasive, clinically-effective, financially-viable, and patient-centric ideas that benefit patients, providers, and payers.
He has sold, built salesforces, funded, and forged strategic partnerships in numerous markets from primary care to endocrine to cardiology to psychiatry to genetics to population health to sports medicine to regenerative health. But his sweetspot markets are ENT and Urology where he created scalable in office procedural models that fueled explosive growth against J&J, AMS, Smith & Nephew, and Medtronic leading to immense value creation for providers and companies during two liquidity events ENTL Nasdaq $70m IPO & subsequent $662m sale to Stryker.
In his spare time you can find him on the water talking business, foiling, or sharing his love for and the beauty that is the "Blue Mindset".